NEW YORK - Actinium Pharmaceuticals (NYSE:ATNM), Inc. (NYSE AMERICAN: ATNM) has announced promising results from the Phase 3 SIERRA trial of Iomab-B, a targeted radiotherapeutic, at the 50th Annual European Bone Marrow Transplant Society Meeting in Glasgow.
The study, which involved patients aged 55 and above with high-risk active relapsed or refractory acute myeloid leukemia (AML), demonstrated that Iomab-B led bone marrow transplants (BMT) produced higher rates of remission and improved overall survival, especially in patients with TP53 mutations.
The TP53 gene mutation is often associated with poor outcomes and resistance to anti-leukemic therapies. The trial showed a median overall survival of 5.49 months for TP53 mutation patients treated with Iomab-B, compared to just 1.66 months for those who did not receive the treatment. The trial's primary endpoint was durable Complete Remission (dCR), and the results indicated significant advancements in this area for patients receiving Iomab-B.
Dr. Hannah Choe, Assistant Professor of Medicine at Ohio State University and a SIERRA trial investigator, noted the high complete remission rates and the ability of Iomab-B to enable access to potentially curative transplantation in this patient population. She emphasized the treatment's tolerability and its potential in inducing high remission rates despite the presence of a TP53 mutation.
The SIERRA trial enrolled 153 patients, with 24% having a TP53 mutation. The data showed that 55.56% of TP53 positive patients achieved complete remission with Iomab-B, a stark contrast to 0% in the control arm. The treatment also demonstrated the ability to overcome TP53 gene mutations, with median overall survival for TP53 negative patients at 6.37 months compared to 5.72 months for TP53 positive patients.
Actinium Pharmaceuticals focuses on developing targeted radiotherapies and holds over 230 patents and patent applications. The company's pipeline includes Iomab-B, an induction and conditioning agent prior to bone marrow transplant, and Actimab-A, a therapeutic agent, both aimed at extending survival outcomes for people with relapsed and refractory AML.
The information in this article is based on a press release statement from Actinium Pharmaceuticals, Inc.
InvestingPro Insights
As Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) shares the promising results of their Phase 3 SIERRA trial for Iomab-B, investors are closely monitoring the company's financial health and stock performance. Based on recent data from InvestingPro, Actinium holds a Price / Book ratio of 5.86 as of the last twelve months ending Q4 2023, indicating a valuation that may be seen as high relative to the company's book value. This could be of interest given the company's niche role in the targeted radiotherapy industry.
InvestingPro Tips suggest that Actinium is a company with more cash than debt on its balance sheet, a positive sign for potential investors looking for financial stability. However, the company is also reported to be quickly burning through cash, which could raise concerns about the long-term sustainability of its operations. Investors should note that while the stock has experienced a strong return over the last three months with a 45.0% price total return, analysts do not anticipate the company will be profitable this year.
For those considering investing in Actinium Pharmaceuticals, it's worth noting that the company does not pay a dividend, which may influence the investment strategy for income-focused portfolios. With these insights, investors can better assess the potential risks and rewards associated with Actinium's stock. For more detailed analysis and additional InvestingPro Tips, visit InvestingPro. And remember, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking even more valuable insights. Actinium Pharmaceuticals currently has 11 additional tips listed on InvestingPro.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.